What is the current market size and future outlook for the cd-19 antibody market?
The CD-19 antibody market size has grown strongly in recent years. It will grow from $1.75 billion in 2024 to $1.91 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to the increasing prevalence of B-cell malignancies, the rise of immunotherapy, the increase in oncology research funding, the emergence of CAR-T cell therapies, the rise in healthcare awareness, and the expansion of personalized medicine.
The CD-19 antibody market size is expected to see strong growth in the next few years. It will grow to $2.70 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to the growing demand for targeted cancer therapies, increasing adoption of smart cell therapies, rising prevalence of hematologic malignancies, expansion of healthcare access in emerging markets, and development of next-generation immunotherapies and improvement in biomanufacturing technologies. Major trends in the forecast period include advancements in antibody-drug conjugates, development of bispecific antibodies, integration of AI in antibody design, improvements in cell-cell therapy platforms, adoption of single-use bioreactors, the emergence of nanobody-based therapeutics, and automation in biologics manufacturing.
Get Your Free Sample of The Global CD-19 Antibody Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21130&type=smp
How has the cd-19 antibody market evolved, and what factors have shaped its growth?
The rising prevalence of B-cell malignancies is expected to propel the growth of the CD-19 antibody market going forward. B-cell malignancies refer to a group of cancers that originate from abnormal B lymphocytes, including conditions such as B-cell lymphomas and leukemias, which affect the immune system and can lead to uncontrolled cell growth. The rising prevalence of B-cell malignancies is attributed to several factors such as the aging population, genetic factors, environmental exposures, lifestyle, improved detection, and immune system changes. CD19 antibody helps treat B-cell malignancies by specifically targeting the CD19 protein on the surface of malignant B cells, leading to their destruction while sparing healthy cells and enhancing the body’s immune response. For instance, in January 2024, according to the American Cancer Society, a US-based non-profit organization, in the USA, around 80,620 people were estimated to be diagnosed with non-Hodgkin lymphoma, and 20,240 people, comprising 44,590 males and 36,030 females, are estimated to die due to non-Hodgkin lymphoma. Therefore, the rising prevalence of B-cell malignancies is driving the growth of the CD-19 antibody market.
What are the major segments of the cd-19 antibody market?
The CD-19 antibody market covered in this report is segmented –
1) By Disease Type: B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Other Disease Types
2) By Type: Polyclonal, Monoclonal
3) By Route Of Administration: Intravenous, Subcutaneous
4) By Application: Enzyme Linked Immunosorbent Assay, Flow Cytometry, Immunohistochemistry Frozen, Immunohistochemistry Paraffin, Other Applications
Subsegments:
1) By B-Cell Non-Hodgkin Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma
2) By Chronic Lymphocytic Leukemia: Relapsed Or Refractory CLL, Treatment-Naïve CLL
3) By Acute Lymphoblastic Leukemia: B-Cell Precursor ALL, Philadelphia Chromosome-Positive ALL
4) By Other Disease Types: Hairy Cell Leukemia, Waldenström’s Macroglobulinemia, Marginal Zone Lymphoma
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/cd-19-antibody-global-market-report
Which companies dominate the cd-19 antibody market?
Major companies operating in the CD-19 antibody market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc, Novartis AG, Thermo Fisher Scientific Inc., Amgen Inc., Bio-Rad Laboratories Inc., Miltenyi Biotec GmbH, Abcam Plc, Kite Pharma Inc., BioLegend Inc., Xencor Inc., Juno Therapeutics Inc., BD Biosciences, Zenas BioPharma Inc., Cell Signaling Technology Inc., Santa Cruz Biotechnology Inc., Novus Biologicals LLC, Tonbo Biosciences Inc., Bio X Cell Inc.
How will evolving trends contribute to the growth of the cd-19 antibody market?
Major companies operating in the CD-19 antibody market are focusing on developing technological innovations, such as genetically modified autologous T-cell immunotherapy, to enhance the efficacy of cancer treatments, particularly for hematologic malignancies. Genetically modified autologous T cell immunotherapy is a treatment where a patient’s own T cells are genetically engineered to recognize and attack cancer cells, then reintroduced into the patient’s body to enhance the immune response against the disease. For instance, in November 2024, Autolus Therapeutics plc, a US-based biopharmaceutical company, announced the U.S. FDA approval for AUCATZYL (obecabtagene autoleucel) indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This design aims to reduce excessive T-cell activation, thereby minimizing toxicity and enhancing the persistence of the therapeutic cells. It is administered as a split-dose infusion on days 1 and 10, with dosing individualized based on a bone marrow assessment prior to treatment.
What are the key regional dynamics of the cd-19 antibody market, and which region leads in market share?
North America was the largest region in the CD-19 antibody market in 2024. The regions covered in the CD-19 antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The CD-19 Antibody Market Report 2025 Offer?
The cd-19 antibody market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
CD19 antibody refers to a monoclonal antibody that specifically targets the CD19 protein, a cell surface marker found primarily on B cells. CD19 is critical in B cell development and is often overexpressed in B cell-related malignancies, such as certain leukemias and lymphomas. These antibodies are used in immunotherapy, including CAR-T cell therapy, to treat cancers by directing the immune system to attack CD19-expressing cells.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21130
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
